In 2021, there are no Chinese pharmaceutical companies in the top ten global generic drug companies. Where is the spring of domestic generic drugs?

The pharmaceutical information website FiercePharm recently released the 2021 global generic drug TOP 10 list (the data in the report does not include biosimilar sale.

Top 10 sales of global generic drug giants in 2021

Source: The TOP 10 generic drug makers by 2021 revenue

Looking at the performance of the top 10 companies in generic drug sales in 2021, 8 of them have increased sales compared to 202 But top-ranked Teva and Sandoz both saw their sales drop 3 perce.

Teva -- sales have fallen for 5 years in a row

Teva Pharmaceuticals is a global pharmaceutical company headquartered in Israel and one of the largest generic drug manufacturers in the wor.

After the 1990s, the competitive pressure of generic drugs in the United States began to gradually increase, further intensified after 2000, and became intensified after 201 For generic drug giants, in order to fully protect their competitive advantages, they can only continue to acquire rivals to reduce competitive pressure and improve their product covera.

Today, while Teva remains a distant leader in generics, its generic sales have declined for five consecutive yea.

In addition to the stiff competition faced by generics and often falling prices, another reason for Teva's decline in generics revenue is divestitur.

Sandoz - whether to demolish or stay, not sure yet

Sandoz was founded in 1886 and was launched in 2003 as Novartis' generics divisi.

Novartis was already considering a sale or spin-off of Sandoz as early as 201 In the past two years, relevant news has never stopp.

Meanwhile, Sandoz's generic sales have been falli.

Sandoz has been looking to expand its business amid the woes of the.

Huizhi--Extraordinarily rich product line

Huizhi was formed by the merger of Mylan and Pfizer Upjohn in 202 In 2021, Huizhi spent a lot of energy on restructuring, involving up to 20% of its global positions and 15 production bas.

Huizhi's generic drug portfolio generated sales of $63 billion in 2021, up 6%, mainly due to performance in the European mark.

It is worth mentioning that Huizhi's product line is extremely rich, and its product portfolio includes more than 1,400 approved molecules, including globally recognized iconic and key brands, generic drugs, complex generic drugs and biosimilar products, covering the heart Cerebrovascular disease, pain and neurological disease, psychiatric disease, urinary disease, liver disease and other therapeutic are.

Indian pharmaceutical companies - four pharmaceutical companies on the list, the overall performance is good

Relatively speaking, the four generic drug companies in India performed well overa.

As the largest generic drug giant in India and the fourth largest in the world, Sun Pharma provides medicines to more than 100 countries around the wor.

.

Aspen--Generic drug sales up 12%

The King of Africa--Aspen has a long history of 160 yea.

With the acquisition of mature product lines of multinational pharmaceutical companies as its business model, Aspen has become the .

1 pharmaceutical company in South Africa and a large multinational pharmaceutical compa.

Its generics performance in 2021 saw a 12% increa.

In 2007, Aspen acquired Strides' Latin America business, forming a 50% joint venture with Strides to develop, manufacture and commercialize a range of oncology products global.

Through this partnership, Aspen will expand into Latin Ameri.

In 2008, Aspen acquired GSK's four core brand products, namely Eltroxin, Imuran, Lanoxin and Zylor.

The agreement gives Aspen access to more than 100 countries around the wor.

In 2011, Aspen acquired the 98-year-old Australian pharmaceutical business of Sigma, making it the largest prescription drug manufacturer in the Australian mark.

Subsequently, tens of billions of dollars were spent to acquire many products from multinational pharmaceutical companies such as GSK, AZ, and Mer.

Where is the way out for Chinese generic drug companies?

According to the data from Min.

com, China's pharmaceutical market is still dominated by chemical preparations based on generic dru.

The generic drug market accounts for about 69% of the overall pharmaceutical market, and the innovative drug market only accounts for

With the advancement of centralized procurement, generic drug companies are gradually desperate: where is the way out?

From the above top 10 pharmaceutical companies in global revenue, it is not difficult to see that one of their main camps is the US mark.

This is because the US has a large market space and good policies, such as a half-year protection system for the first generic drugs, including encouraging hospital pharmacies and pharmacies to use generic dru.

Therefore, it is inevitable for domestic generic drug companies to survive, develop, go abroad, and compete with those top generic drug compani.

In addition, and more importantly, looking at the major generic drug giants, from Teva to Sandoz to Aspen, all of them are developed through acquisitio.

China's pharmaceutical companies have not yet undergone major mergers or acquisitio.

In the future, if China's generic drug companies want to become bigger and stronger, integration is inevitab.

This requires that the integrator either needs to have a strong capital operation ability, or needs to have funds, or needs a strong operation abili.

At present, China's pharmaceutical industry is still in a critical period of high-quality development, transformation and upgrading, and the innovation ecology of the industrial chain is still immatu.

Truly making first-in-class breakthrough innovative drugs is always a game for a few companies and a few peop.

Every company faces different problems in its transformation and upgrading, and its strategies and path choices are differe.

Whether pursuing high-end innovation, ensuring access to medicines, or seeking leapfrog development through capital mergers and acquisitions, the pursuit of value will always be at the core of meeting clinical nee.

Main reference: The TOP 10 generic drug makers by 2021 revenue